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Abstract
Protein isoforms produced by alternative splicing (AS) of many genes have been implicated in
several aspects of cancer genesis and progression. These observations motivated a genome-wide
assessment of AS in breast cancer. We accomplished this by measuring exon level expression in
31 breast cancer and nonmalignant immortalized cell lines representing luminal, basal and
claudin-low breast cancer subtypes using Affymetrix Human Junction Arrays (HJAY). We
analyzed these data using a computational pipeline specifically designed to detect AS with a low
false positive rate. This identified 181 splice events representing 156 genes as candidates for AS.
RT-PCR validation of a subset of predicted AS events confirmed 90%. Approximately half of the
AS events were associated with basal, luminal or claudin-low breast cancer subtypes. Exons
involved in claudin-low subtype-specific AS were significantly associated with the presence of
evolutionarily conserved binding motifs for the tissue-specific Fox2 splicing factor. siRNA
knockdown of Fox2 confirmed the involvement of this splicing factor in subtype specific AS. The
subtype specific AS detected in this study likely reflects the splicing pattern in the breast cancer
progenitor cells in which the tumor arose and suggests the utility of assays for Fox-mediated AS in
cancer subtype definition and early detection. These data also suggest the possibility of reducing
the toxicity of protein-targeted breast cancer treatments by targeting protein isoforms that are not
present in limiting normal tissues.
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Introduction
Breast cancer is a heterogeneous disease that demonstrates considerable variability in
response to existing therapies. Recent advances in genome characterization and
transcriptome profiling techniques have defined distinct molecular subtypes of breast cancer
that differ in biological characteristics and clinical outcome. Subtypes defined through
analysis of transcriptional profiles have been designated basal, luminal A and luminal B,
ERBB2, normal (1,2) and more recently, claudin-low(3,4). Like basal tumors, claudin-low
tumors are generally triple negative (ER−, PR−, ERBB2−). However they uniquely express
low levels of tight and adherens junction genes including Claudin 3 and E-cadherin and
often highly express markers associated with epithelial to mesenchymal transition (EMT)
(3,4). Definition of breast cancer subtypes is important to efforts to improve prognostic and
predictive markers and to identify new therapeutic targets. The transcript-level measures of
gene expression used for subtype definition so far have been important in these areas but
may be incomplete indicators of gene function or cellular phenotype because they fail to
account for important differences in RNA structure generated by alternative RNA
processing events. Alternative transcription initiation or termination events frequently alter
the coding capacity at the N- or C-terminal ends of proteins, whereas alternative pre-mRNA
splicing of cassette exons can alter expression of functionally important internal domains. In
fact, recent studies of human transcriptome suggest that more than 90% of human genes are
processed to produce alternative transcript isoforms via one of these mechanisms (5,6) and it
is becoming clear that AS is important in the development of the pathophysiology of many
human cancers (7).
Information about AS in cancer comes from cDNA sequencing, exon level microarray
analysis and RNA sequencing using massively parallel sequencing techniques (5,6,8). A
recent assessment of estrogen receptor positive (ER+) breast cancer using high throughput
RT-PCR identified a number of alternative splicing events that differed between tumors and
normal tissue (9). In this report we assess AS in a panel of 26 breast cancer cell lines
representing three different tumor subtypes representing the luminal, basal and claudin-low
subtypes in primary breast tumors (3,10) and 5 non-malignant breast cell lines. We assessed
AS by computational analysis of exon level expression profiles measured using the
Affymetrix Human Junction Array (HJAY) technology (11,12) and we applied RT-PCR and
deep RNA sequencing for validation. These studies identified 156 AS genes including ~40%
for which splicing differed between the luminal, basal and claudin-low transcriptional
subtypes. Analysis of the genomic context of alternatively spliced exons suggested Fox1/
Fox2 family proteins as regulators of AS. Together these observations suggest the existence
of a subtype specific AS program in breast cancer that may be exploited therapeutically and
diagnostically.
Methods
Cell lines collection
Breast cancer cell lines used in this study were obtained from the ATCC or from collections
developed in the laboratories of Drs. Steve Ethier and Adi Gazdar and have been carefully
controlled for quality and identity as described in (10). We analyzed alternative splicing
using microarrays in 26 breast cancer cell lines and 5 non-malignant immortalized human
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mammary epithelial cells (HMEC) cultured as described previously (10,13). The 26 breast
cancer cell lines were comprised of 13 having transcription level profiles similar to luminal
breast cancers, 6 classified as basal and 7 classified as claudin-low. Five cell lines in our
collection (184A1, 184B5, MCF10A, MCF10F, and MCF12A) represented non-malignant
immortalized cell lines derived from abnormal but not cancerous tissues.
For RT-PCR validation of predicted AS events we expanded the cell line collection to
include 48 breast cancer lines of basal, luminal and claudin-low subtypes as well as 4
normal finite lifespan HMEC strains. The latter included 184D, 48RT, and 240LB strains,
which were obtained from reduction mammoplasty tissues and were shown to have mixed,
predominantly basal phenotypes, and the 250MK derived from aspirated milk fluids. Garbe
et al have demonstrated that 250MK cells express luminal markers and thus represent the
luminal subtype (14).
Affymetrix Human Junction Array design and data processing
Genome-wide, exon-level expression and alternative splicing were analyzed using
Affymetrix GeneChip® Human Junction Arrays (HJAY, a noncommercial format in
collaboration with Affymetrix (Santa Clara, California)). The HJAY array platform was
designed using content from ExonWalk (C. Sugnet), Ensembl, and RefSeq databases (NCBI
build 36). It interrogates ~315,000 human transcripts from ~35,000 genes and contains
~260,000 junction (JUC) and ~315,000 exonic (PSR) probe sets. A fraction of probe sets
had non-unique locations in the human genome and were likely to give cross-hybridization
signal. These were excluded from our analysis. In total 501,557 of probesets from 23,546
transcript clusters were retained. Transcript clusters were assigned to known genes using
database table refFlat.txt of the UCSC Genome Browser (http://genome.ucsc.edu/). The
HJAY data was pre-processed using Affymetrix Expression Console™ Software. Probe set
level expression measurements were generated from quantified Affymetrix image files
(“.CEL” files) using the RMA algorithm (15). The cell lines in the collection were analyzed
simultaneously creating a data matrix of probe sets log2 expression values in each cell line.
Transcript level expression levels were generated by averaging exonic probesets (PSRs)
measurements in that cluster.
Affymetrix Microarray Profiling
HJAY profiling of cell lines was performed using the GeneChip® Whole Transcript (WT)
Sense Target Labeling Assay Kit (Affymetrix). An initial step to remove ribosomal RNA
was used to minimize background and to increase detection sensitivity and specificity.
Ribosomal RNA subtraction was conducted using a protocol that was modified by
Affymetrix for the RiboMinus Transcriptome Kit (Invitrogen). Diluted poly-A RNA
controls and RiboMinus probe (in a betaine-containing hybridization buffer) were added to
2ug of total RNA from each sample, incubated at 70C for 5min and then cooled on ice.
RiboMinus magnetic beads, prepared by a batch method, were added to the samples and
incubated at 37C for 10min. The beads containing the rRNA were isolated using a magnetic
separator and the supernatant was transferred to a fresh tube. The beads were washed,
separated, and the supernatant was added to the tube. IVT cRNA cleanup columns
(Affymetrix) were used to concentrate the subtracted RNA to a volume of 9.8ul. Probe
synthesis, oligonucleotide array hybridization and scanning were performed according to the
standard Affymetrix GeneChip® protocol for the WT Sense Target Labeling Assay with
Control Reagents (rev. 2). Double-stranded cDNA was synthesized with random hexamers
tagged with a T7 promoter sequence and used as a template in the presence of T7 RNA
polymerase to produce cRNA. In the second cycle of cDNA synthesis, random hexamers
were used to reverse transcribe cRNA from the first cycle, producing single-stranded DNA
(ssDNA) in the sense orientation. The ssDNA was fragmented by the uracil DNA
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glycosylase and apurinic/apyrimidinic endonuclease 1 which recognizes the dUTP
incorporated in the ssDNA during the second-cycle, first-strand reverse transcription
reaction, and breaks the DNA strand. The fragmented ssDNA was labeled with terminal
deoxynucleotidyl transferase and a DNA labeling reagent that is covalently linked to biotin.
The fragmented, biotinylated ssDNA probes (5.5ug) were hybridized in a volume of 220ul at
45°C for 16 hours to Affymetrix high density Human Junction Arrays. The arrays were
washed and stained with streptavidinphycoerythrin (SAPE, final concentration 10 µg/ml).
Signal amplification was performed using a biotinylated anti-streptavidin antibody. The
arrays were scanned on an Affymetrix GeneChip® Scanner 3000 7G scanner with an
autoloader, according to the Affymetrix GeneChip® WT Sense Target Labeling Assay
protocol for the GeneChip® Exon 1.0 ST array. Scanned images were inspected for the
presence of obvious defects (artifacts or scratches) on the array; none were detected. The
raw and processed expression and splicing data is available at the ArrayExpress data
repository with accession number E-MTAB-183.
Detection of differential splicing using microarray data
We developed an analysis pipeline to detect alternately spliced probesets in microarray data
as follows:
Data filtering—Probeset and gene level expression data were filtered to remove noisy data
that might contribute to false positives. Briefly, we required: (a) expression above the
background in at least 25% of samples; (b) probeset exhibiting differential expression; (c) at
least 3 probe sets per transcript cluster exhibiting expression above the background to ensure
correct FIRMA linear model fitting (see below).
Splicing Index—We calculated a Splicing Index (SI) using filtered probeset level
expression data according to the formula:
where ei,j,k is the expression level of the i probeset, in experiment j, within the kth transcript
cluster. gj,k is the transcript cluster expression level estimate of the j experiment and k
transcript cluster calculated as the mean of expression of its probesets in a given experiment
(sample). Transcript clusters differed substantially in the level of SI variation of their probe
sets. Clusters with high variation in many probesets were unlikely to represent clear
alternative splicing cases. To avoid prioritization of such clusters in the downstream
selection process we converted the splicing index to a Normalized Splicing Index (NSI) data
according to the formula:
where Ñk is a measure of a transcriptional noise within a given transcript cluster within a
sample set. It is estimated as a median of the following values:
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where Ni,k is the SD of expression of a probeset i within a transcript cluster k, m is the
number of samples, μj,k is the mean of ei,j,k.
Selection of highly variable probesets—NSI data was used to select probesets with
the highest variability among cell lines due to alternative splicing. We computed a
variability score for a probeset i, from transcript cluster k using standard deviations of NSI
and expression of probesets across samples according to the formula:
where m is the number of samples,  and μi,j are the means of NSIi,j,k and ei,j,k
respectively. We selected probesets with the highest 1% of variability scores. This
conservative selection strategy likely misses many valid AS events however, it increases the
probably that AS calls are valid. In total 2783 probesets from 1760 transcript clusters passed
this cutoff.
Selection of statistically robust AS probesets using FIRMA—We used a minor
modification of the program FIRMA (16), to assess robustness of the highly variable
probesets selected as described above. FIRMA tests the consistency of expression pattern of
all probes within a transcript cluster within sample set. For each gene FIRMA fits the
following additive model, to background corrected and normalized log2(PM) values:
where ci is the chip effect (expression level) for chip i, pj is the probe effect for probe j, eij is
a random error and log2(PMij) is the log (base2) of the background–corrected, normalized
perfect match (PM) signal for probe j on chip i.
The model is fitted using iteratively reweighted least squares (IRLS) (17), as implemented in
the R function rlm. rlm returns parameter estimates, weights and residuals at convergence.
The weights and residuals can be used for detection of probe sets that behave inconsistently
with other probesets within a transcript– likely due to differential splicing. Instead of using
residuals as described in the Purdom et al (16) we used weights that ranged from 0 (strong
evidence of AS) to 1 (no AS). Based on the careful observation of the data, we set an
arbitrary cut off of wi,j ≤0.7 for an indication of alternative splicing taking place at a given
probe set in a given sample. To generate FIRMA weights data for pre-selected highly
variable probesets, we ran the FIRMA algorithm using R function rlm on a subset of 78,050
probe sets. These were all unique probesets from the 1760 candidate transcript clusters
described above.
Selection of the best AS candidate events—The 2783 most variable probesets were
further filtered to select most reliable alternatively spliced events within the breast cancer
cell lines. Out of 2783 probe sets, we retained those that had: (a) FIRMA weights wi,j of
≤0.7 in at least 10% of cell lines; (b) average probeset expression of log2 ≥5.9; and (c)
belonged to a transcript cluster mapped unambiguously to a known gene. We grouped the
remaining probesets based on the location within the genome. Probesets located within
150bp from each other, were considered to describe the same AS event. This process yielded
392 probe sets belonging to 181 alternative splice events of ≥2 probesets within 156 known
genes.
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Selection of differentially expressed transcript clusters using microarray data
We used the transcript cluster level expression data to identify genes that were differentially
expressed among the breast cancer cell lines. Clusters with consistently low expression in all
cell lines were excluded from the analysis (expression value cut off was log2=3). We
measured the variability of expression for every transcript cluster on the array by calculating
the CV of expression among cell lines. We ranked transcript clusters according to these
values and selected those with the highest CVs. This yielded 224 known genes with CV ≥
0.3.
Pathway, protein networks and GO terms enrichment analysis
We used the DAVID Functional Annotation tool (18,19) and Ingenuity Pathway Analysis
(IPA) software (Ingenuity®Systems, www.ingenuity.com) to perform enrichment analysis
for 156 best AS genes and 224 top differentially expressed genes. GO enrichment was also
performed with DAVID with a Benjamini Hochberg adjusted p-value cut off of ≤0.01. The
Ingenuity knowledge base includes an extensive library of well characterized signaling and
metabolic pathways and was used for pathway and network enrichment analysis. Of the 156
AS candidate and 224 differentially expressed genes, 140 and 222, respectively were well
annotated in IPA 6.0 database and used for comparative pathway enrichment analysis.
Human Genome U133A array data was used as a reference to rank top statistically
significant over-represented canonical signaling and metabolic pathways in both sets.
Fisher’s exact t-test was applied to examine the statistical over representation of pathways,
using a threshold of Benjamini Hochberg adjusted p-value ≤ 0.05. Further, the genes of
interest were overlaid onto the global molecular network developed from information
contained in Ingenuity’s Knowledge Base to identify networks that were significantly
enriched. These networks are algorithmically generated based on their connectivity. These
networks were analyzed further to identify the major nodes (genes in each network with the
highest number of interactions with other genes) and the functions associated with the genes
in the network. The Functional Analysis of a network identified the biological functions that
were most significant to the molecules in the network. The network molecules associated
with biological functions in Ingenuity’s Knowledge Base were considered for the analysis.
Right-tailed Fisher’s exact test was used to calculate a p-value determining the probability
that each biological function assigned to that network is due to chance alone.
Nucleic Acid Isolation
Total RNA was extracted from cells grown in 10cm dishes under the standard conditions for
each cell type, using the RNeasy Mini Kit (QIAGEN Inc., Valencia, CA). Cell lysis was
performed in 600uL RLT Buffer with mechanical shearing; the RNA was recovered
according to manufacturer’s instructions.
RT-PCR validation
Primer design—Primers were designed using Primer3 software (20) within constitutive
exons immediately upstream and downstream of predicted alternatively spliced exons. In
instances of alternative terminal exons, a unique primer was designed in each terminal exon
and amplified towards a common constitutive exon primer. Validation was performed using
a panel of 48 cell lines and 7 primary breast tumors. For primers sequences see Suppl.
Materials.
RT-PCR—3ug of total RNA from each cell line and 1ug from each primary tumor was used
to produce cDNA primed with random hexamers in a 20uL volume using the SuperScript III
First Strand Synthesis Kit (Invitrogen) with standard protocols. An aliquot of the resulting
cDNA (0.5ul) was used in each 10uL PCR reaction using specific primers. PCR was carried
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out with the same conditions for 35 cycles: 35 seconds at 94°C, 35 seconds at 55°C, and 60
seconds at 72°C. The PCR products (4ul) were separated on 5% polyacrylamide gels using a
Dual Triple Wide Mini-Vertical Electrophoresis System (CBS Scientific) and imaged.
Fox2 knock down experiments—Breast cancer cell lines at 55–65% confluency were
transfected with Fox2-specific siRNA (Fox2 On-TARGETplus SMARTpool L-020616-01)
or control siRNA (On-TARGETplus Non-Targeting Pool; D-001810-10-05) from
Dharmacon. Transfection was performed with 25nM siRNA using Dharmafect I
Transfection Reagent according to the manufacturer’s instructions (Dharmacon). After 48hrs
RNA was isolated as described above. Equal amounts of RNA from control and knockdown
cell were analyzed by semiquantitative RT-PCR to evaluate changes in alternative splicing
of candidate Fox2-regulated exons.
Deep sequencing of cell lines transcriptomes using Illumina technology
Total RNA was extracted from MCF7 and BT549 cells using Qiagen’s RNeasy Mini Kit. An
early version of Illumina’s mRNA-Seq protocol was used to prepare the sequencing
libraries. For details, see Supplementary Data. 19,553,572 reads of 32bp length were
obtained for the BT549 sample and 18,747,831 for MCF7. ELAND was used to align the
reads to the HJAY probeset sequences, which were used as a reference. For mapping
procedure details see Supplementary Data. Probesets expression level were derived from
read count data (number of reads mapped to the reference sequence) by normalizing for the
reference sequence length. Since the minimal reference sequence length was 32 bp we
defined a normalized read count (NRC) data as:
where RC is the raw read count data and L is the length of reference sequence in bp. NRC
data was filtered to remove unreliable low coverage probesets from further analyses. We
required, that a reference sequence (a probeset from HJAY array) had the sum of NRC
between two cell lines of ≥ 1, which roughly corresponded to 2 mapped reads per average
58 bp JUC probe. Next, NRC data was log2 transformed to make it comparable with the
microarray log2 scale expression summaries:
Further, expression estimates using both Illumina technology and Affymetrix microarrays
were used to generate AS calls. First, log2 expression values for each of the two cell lines
have been transformed to SI values. Second, probeset-wise SI score differences have been
calculated for the pair of cell lines for each platform. A probeset that had a SI score
difference at least one standard deviation away from the mean of SI differences of all
probesets in that gene was called AS.
We tested the overall agreement of the two platforms expression profiles and ability to
measure differential expression. Between platforms correlations of expression values and
log2 ratios were comparable to those published before for microarray platform comparisons
(Spearman correlation of 0.5–0.7 (21) and for microarray-sequencing platforms comparisons
(Spearman correlation of 0.73–0.75 (22). Second, we determined if the best 181 splice
events could be validated with Illumina technology. This comparison revealed that 59% of
well expressed genes were detected with sequencing technology and the set of the best AS
candidates was significantly enriched with differential splicing signal from both platforms
(Chi-squared test, Χ2=489.5, df = 1, p-value < 2.2e-16). For details see Supplementary Data.
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Results
Detection of alternative pre-mRNA splicing in breast cancer cell lines
We measured exon level transcriptional profiles for 5 non-malignant immortalized breast
cell lines and 26 breast cancer cell lines including 13 classified as luminal, 6 classified as
basal (1,2) and 7 classified as claudin-low (3). The 5 nonmalignant immortalized lines were
classified as basal. Exon level expression was assessed using the Affymetrix HJAY platform
(11,12) that measured expression levels for ~315,000 known exons and ~260,000 exon
junctions (for array design details see Methods). We used a computational pipeline designed
to detect hallmarks of probeset expression associated with alternative pre-mRNA splicing
events among the cell lines. The pipeline utilized two techniques, Splicing Index (SI)(23)
and Finding Isoforms using Robust Multichip Analysis (FIRMA)(16). The SI provided a
quantitative measure of differential exon level expression along each gene independent of
the transcript level expression. FIRMA assessed differential splicing status of every probeset
within a transcript in a statistically robust manner so that it identified those probesets
(exons) whose expression pattern across samples did not follow overall transcript expression
pattern across the same samples. We included probeset (exon) level and transcript level
filtering to remove probesets that exhibited high background, high level cross hybridization
and/or weak hybridization (for details see Methods) in order to reduce the false positive rate
in AS detection. Finally, we added post-processing to select the top 1% of probesets (exons)
showing the most prominent differential splicing among the cell lines that mapped to
annotated genes and that exhibited significant AS in at least 10% of the cell lines as
measured by FIRMA. This analysis identified 181 splice events (supported by 392
probesets) and implicated 156 known genes as alternately spliced among the cell lines
(Supplementary Table 1). Figure 1 shows an example of alternative splicing predicted in the
SLK (STE20-like kinase) gene, as represented by the normalized splicing index (NSI) for
exons distributed across the gene. The alternatively spliced exon in the center of the gene is
preferentially skipped in cell lines of the claudin-low subtype (depicted by red lines) as
indicated by the low splicing index for probesets interrogating the alternative exon itself and
its junction with the downstream exon (upper panel), and the relatively higher splicing index
for the junction probe interrogating the exon skipping event (lower panel).
We performed hierarchical clustering of the 392 AS probesets to identify recurrent AS
patterns among the cell lines. Figure 2 shows three distinct clusters that are mostly
concordant with the basal, luminal, and claudin-low subtypes defined previously using
hierarchical clustering according to overall gene transcription level (3,4). Non-malignant
immortalized mammary epithelial lines clustered together with basal subtype cell lines.
Application of the standard Students t-test (Benjamini-Hochberg adjusted p-value <0.05) to
NSI data for the 392 AS probe sets identified 74 (out of 181) splicing events that correlated
with a breast cancer subtype. As expected, reciprocal behavior was observed for probesets
representing exon inclusion and exclusion events (Figure 2, cluster D).
We tested the validity of predicted AS using deep sequencing and RT-PCR. Deep
sequencing of one claudin-low (BT549) and one luminal (MCF7) cell line was performed to
obtain ~19 million 32bp sequence reads from each cell line. Analysis of these data validated
~60% of HJAY microarray-predicted splicing differences among the highly expressed genes
(See methods and Supplementary Data). However, the cost of sequencing needed to validate
AS in transcripts of moderate or low abundance was prohibitive so we used RT-PCR to test
12 subtype-specific AS predictions across an expanded panel of 7 basal, 14 claudin-low, 18
luminal, 5 non-malignant immortalized breast cell lines and 4 normal finite life span HMEC
strains. The AS events selected for verification included cassette exons, alternative 5’ and 3’
ends, and tandem cassette exons. Table 1 and Figure 3 show that 11 of the 12 AS predictions
exhibited splicing differences among the cell lines. In addition to these, 8 other predicted AS
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events were used in Fox2 knock-down experiments and 7 of them showed alternative
splicing in a smaller panel of 12 cell lines representing the same cancer subtypes (Fig 5B,
additional AS events CLSTN1-57nt, CLSTN1-30nt, KIF21A, PLOD2, ST7, MARK3, ENAH
and VPS39). Thus the validation rate of our predictions was ~90% (total of 18 out of 20),
which supported the robustness of our computational detection strategy for prediction of AS
using HJAY profiles. In general, the claudin-low cell lines consistently showed a different
splicing pattern than the basal and luminal subtypes due to differences in the regulated
alternative splicing of internal cassette exons.
Mechanism of Breast Cancer Subtype-specific Splicing
A substantial literature supports the concept that differentiated normal cells execute cell
type-specific alternative splicing programs to tailor the structure and function of encoded
proteins to the needs of individual cells. One particularly striking observation in this regard
is the increased frequency of the binding site, UGCAUG, for the Fox1/Fox2 class of splicing
factors, in the introns adjacent to tissue-specific alternative exons in muscle, brain, and
erythroid cells compared to introns adjacent to constitutively spliced exons or non tissue-
specific alternative exons (11,24–28). The recurring association of this Fox binding site
(UGCAUG) with tissue-specific alternative exons suggests an important role in regulation of
alternative splicing. These reports motivated our investigation of the possibility that Fox1/
Fox2 class splicing factors also influence breast cancer subtype specific splicing.
The importance of Fox1/Fox2 regulation of subtype specific splicing in breast cancer is
supported by the plot of the expression levels of Fox2 in Figure 2 that shows that its
expression is significantly elevated in basal and claudin-low subtypes compared to luminal
subtype cells. We further explored the role of Fox2 class splicing factors in breast cancer
subtype specific splicing by assessing the presence of the consensus Fox binding site,
UGCAUG, in 22 internal alternative exons for which at least two probesets supported
differential alternative splicing between luminal vs. basal and/or claudin-low cells
(Supplementary Table 1). Remarkably, Figure 4 shows that 19/22 of these exons possessed
one or more UGCAUG binding site in the intron sequences within 400nt of the differentially
expressed exons. This frequency greatly exceeded that expected for a random hexamer,
which should occur only once every 4kb, or in one out of five such cases. In addition, some
exons lacking these more proximal UGCAUG motifs possessed Fox binding sites more
distally. In two cases (ENAH, ST7), clusters of predicted Fox2 binding sites were located in
the long downstream intron between 1.4–1.8kb from the regulated exon. While these sites
are more distant than most described splicing enhancers, there is precedent for functional
Fox sites >1kb from the regulated exon (29).
The functional significance of these associations is further supported by the observation that
the Fox binding sites are highly conserved in evolution (Figure 4). In 18/22 cases, orthologs
of genes (including the three with distal Fox sites) displaying subtype specific splicing
encoded conserved Fox binding sites in the same relative intronic regions. Phylogenetic
conservation of intronic UGCAUG motifs in some cases extended not only within
mammalian genomes, but also to other vertebrate orders including avian (chicken),
amphibian (frog), reptilian (lizard), and fish (zebrafish) species. This result strongly supports
the functional importance of Fox binding sites near subtype-associated exons.
To further explore whether Fox2 regulates breast cancer subtype-specific splicing, we asked
whether siRNA knockdown of Fox2 altered the splicing efficiency of putative target exons
by evaluating the effect on AS of treating a non-malignant immortalized mammary
epithelial cell line and cell lines representing the three breast cancer subtypes with siRNAs
against Fox2 or an irrelevant siRNA. The Fox2 siRNA consistently reduced expression by
75–80% as determined by qRT-PCR (Figure 5A). Splicing changes induced by Fox2
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knockdown were then examined for fourteen subtype-specific alternative exons in four
representative cell lines from each of the luminal, basal, and claudin low subtypes (Figure
5B). This analysis showed (a) that the majority of subtype-specific exons predicted to be
Fox2-regulated did indeed exhibit differences in splicing efficiency when Fox2 was knocked
down, and (b) that splicing responses between subtypes was often distinct, while responses
within each subtype were generally very consistent. In most cases (11 of 14 exons), lower
Fox2 mRNA expression correlated with reduction in splicing efficiency of the target exons.
The relative effects of Fox2 knockdown were large for some exons, such that exon inclusion
was almost eliminated (e.g., CLSTN1, 57nt). In other cases, effects were modest but
reproducible among cell lines representing the same subtype (e.g., ST7). Inclusion of one
exon (in FAM62B) was modestly increased under the same conditions, while two exons (in
FER1L3 and VPS39) were little affected. These observations indicate that Fox2 functions
predominantly as a splicing enhancer in these cells. Control siRNA did not affect any of
these splicing events. We conclude that Fox2 activity plays a major role in regulating a set
of breast cancer subtype-specific alternative splicing events, as predicted by the associated
consensus binding sites.
Fox2 enhancer activity was detected most frequently in claudin low cells, with eight exons
exhibiting marked Fox2-dependence in exon inclusion levels (CLSTN1-57 and -30, KIF21A,
PLOD1, ST7, FAT, TJP1, MARK3). Evidence for Fox2 enhancer effects on the same set of
exons was often but not always observed in basal cells even though Fox2 is relatively highly
expressed in both in claudin low and basal subtypes (Figure 2). Interestingly, a few exons
that were predominantly skipped in claudin low cells paradoxically exhibited Fox2-
dependent splicing in luminal cells even though this subtype has lower Fox2 expression.
This feature was most evident for ENAH, but was also reproducibly observed as a minor
effect in CLTC and SLK. These results indicate that Fox2 cannot be the sole determinant of
subtype-specific splicing. Presumably, subtype-specific differences in Fox2-dependent
splicing efficiency reflect combinatorial effects of multiple splicing regulators with
antagonistic or synergistic activities, each with its own subtype-specific activity profile,
together with exon-specific constellations of binding sites for these factors.
Important pathways and networks affected by alternative splicing
We analyzed 156 alternatively spliced genes detected in breast cancer cell lines using the
DAVID functional annotation tool (http://david.abcc.ncifcrf.gov) (30,31) and Ingenuity
software (http://www.ingenuity.com) and compared these to 224 genes that were
differentially expressed among the cell lines. In general, AS involved different genes than
differential expression since only 2 genes were in common between these lists. Analyses of
AS genes showed preferential enrichment of biological processes related to cytoskeleton and
actin. This held true for the 156 gene list and a subset of 63 genes showing subtype specific
AS. The Ingenuity pathway enrichment analysis implicated AS in aspects of signaling
involving Axon guidance, Ephrin receptor, Integrin and Tight Junctions (Figure 6, Table 2).
The top three protein networks that were highly enriched with AS genes had major nodes
involving MYC, Actin and EGFR genes. The main functions associated with the merged
network were cytoskeleton organization, biogenesis and cell signaling (Figure 2 in
Supplementary Materials). On the other hand, Figure 6 shows that 224 differentially
expressed but not alternately spliced genes predominantly influenced aspects of metabolism.
Discussion
Alternative splicing of pre-mRNAs is now well established as a mechanism for increasing
protein functional diversity during normal development. In addition, alternative splicing
events (ASEs) have been implicated specifically in breast and ovarian cancer genesis and
progression by PCR screening for cancer associated known ASEs listed in a RefSeq
Lapuk et al. Page 10
Mol Cancer Res. Author manuscript; available in PMC 2011 July 6.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
database of known isoforms (28). These studies identified over 200 breast cancer specific
ASEs that were spliced differently in ER+ tumors vs. normal tissue (32). Moreover, the
splicing factor, Fox2, has been associated with normal tissue specific splicing (24) and has
been implicated as an important splicing factor in breast and ovarian cancer development
(32). We extended these findings here by interrogating alternative splicing in a collection of
breast cancer cell lines that exhibit transcriptional programs found in breast cancers
classified as luminal (ER+), basal (ER−) and claudin-low (ER− with stem cell like features)
using splice-sensitive Affymetrix HJAY microarrays. Our analysis implicated 156 genes as
alternately spliced including 63 whose splicing patterns were associated with the luminal,
basal and claudin-low subtypes.
In order to understand the role of splicing in global regulation of cellular processes, we
performed a pathway, GO terms and protein network enrichment analysis for 156 genes with
strongest evidence of alternate splicing across breast cancer cell lines. We observed a
significant enrichment for pathways involving axonal guidance, integrin signaling, tight
junction signaling, Ephrin receptor signaling, and actin cytoskeleton (Figure 6, Table 2) and
GO terms mostly related to cytoskeleton and actin. The involvement of the cytoskeleton in
morphology and motility suggests the possibility that alternative splicing plays a significant
role in determining phenotypic differences between these breast cancer subtypes (10,33).
Interestingly, we found that genes and the biological processes influenced by alternative
splicing were different from those influenced by expression regulation. In general,
alternative splicing influenced aspects of cell surface protein mediated signaling that
affected morphology and motility while differential gene expression seemed to influence
metabolism and signaling controlling cell proliferation. This is in line with earlier
observations that splicing and transcription regulation mechanisms function in parallel to
mediate cellular processes (34,35). The importance of AS in protein function regulation is
supported by the theoretical protein structure analysis of Wang et al showing that ~90% of
AS regions are located within regions of “loop” secondary structures on the surface of
proteins and thus likely mediate protein-protein and protein-ligand interactions (36) In
addition, Hughes and Friedman showed that AS genes tend to interact with other AS genes
in genetic and protein interaction networks (37). Taken together, our data and the published
literature suggest that AS plays an important role in the formation and regulation of protein-
protein interactions involved in cell motility and morphology(38).
Expression of Fox2 is associated with subtypes showing up-regulation of expression in
claudin-low and basal cells and down regulation in luminal cells. This observation suggests
that Fox2 is an important regulator of subtype specific splicing differences between luminal
and basal/claudin-low subtypes. Evidence for this includes (a) moderate association between
increased Fox2 expression and internal exon cassette inclusion in the non-luminal subtypes
(Pearson’s correlation of 0.5), (b) evolutionary conservation of intronic Fox2 consensus
binding sites and (c) reduced inclusion of target exons in non-luminal subtype cells after
treatment with a siRNA against Fox2. Notably, even the ST7 alternative exon having a
cluster of three distal intronic Fox binding sites ~1.8kb downstream exhibited reduced
splicing efficiency when Fox2 expression was reduced by siRNA knockdown. However, it
is clear that Fox2 is not the only regulator of subtype specific splicing events, since there
was a wide range of Fox2-dependence in splicing efficiency among the tested exons, and a
few were insensitive to changes in Fox2 expression. Individual exons in the the subtype-
specific splicing programs are likely regulated by a combination of factors with antagonistic
and/or synergistic activities that can fine tune the distributions of spliced forms for each
subtype. In particular, the recently described epithelial splicing regulatory proteins ESRP1
and ESRP2(39,40) are good candidates for contributing to subtype-specific splicing
programs.
Lapuk et al. Page 11
Mol Cancer Res. Author manuscript; available in PMC 2011 July 6.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
A comparison of the 156 alternately spliced genes revealed by our study with the 247 genes
listed by Venables et al as alternately spliced in breast cancer shows only 10 that are
common to both studies. This is not surprising since the experimental designs and sample set
composition used in our studies differed from those used by Venables et al. For example,
Venables et al used a sensitive PCR based approach able to detect alternately spliced
isoforms present at a level of 10% of the total amount of all transcripts while we used a
microarray approach that is relatively insensitive to the presence of low abundance
transcripts. In addition, we focused on alternative splicing differences between cell lines
derived from both ER+ positive and ER-negative (ER−) breast tumors while Venables et al
focused on the detection of tumor specific splice events that differed between ER+ tumors
and normal tissues. As a result, the ER+ breast cancer specific splice isoform markers found
by Venables and splice specific markers of breast cancer subtypes discovered in our study
provide a more comprehensive picture of the role of AS in breast cancer pathophysiology. A
combination of the approaches seems appropriate for future splicing studies.
Finally, information about subtype specific alternative splicing of cell surface proteins in
breast cancer may have important translational applications. In this study, these included cell
surface proteins encoded by the genes CD47, CLTC, DST, FAM62B, FAT, FER1L3, FLNB,
MET, PLEC1, PPFIBP1 and PTPRK. Molecular assays for specific protein isoforms for
these genes may increase the sensitivity and specificity of anatomic and blood based
detection of specific breast cancer subtypes. Subtype specific cell surface protein isoforms
also are attractive candidate therapeutic targets since agents that specifically attack a cancer
specific protein isoforms may have reduced reactivity with other protein isoforms that are
expressed in otherwise rate limiting normal tissues. Genes showing strong claudin-low
specific alternative splicing including FLNB and FAT are interesting as targets for stem cell
specific therapies considering that the claudin low cells carry many molecular features
associated with stem cell function (41). Targeting this breast cancer subtype is highly
important given the growing evidence that such cancers may be particularly resistant to
conventional therapies. (42). Supplementary Table 1 describes alternative exon usage in
alternatively spliced cell surface proteins to guide efforts to develop subtype specific
markers and therapies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Alternative Splicing for SLK
The probeset NSI data for two isoforms are plotted separately as functions of distance along
the genome. Data for the inclusion isoform is shown above the exon-intron cartoon and data
for the exclusion isoform is shown below it. The AS region between the vertical black lines
involves a single alternative exon. The AS region is expanded to make AS events more
clear. Probesets interrogating exonic regions and respective junctions are shown with
vertical dotted lines. Subtypes of cell lines are color coded so that claudin-low results are
red, basal results are blue, luminal results are green and HMEC results are grey. NSI values
show that the exclusion isoform is prominent in claudin-low cell lines and diminished in the
luminal and basal subtypes; conversely, the inclusion isoform is diminished in claudin-low
and prominent in two other subtypes.
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Figure 2. Unsupervised hierarchical clustering of AS predictions
392 probeset NSI data from 156 genes have been clustered. Three major gene clusters A, B
and C expanded on the right show distinct subtype specific AS patterns. Cluster D at the
bottom shows the FAM62B gene used for PCR validation. Preferential exclusion of an
alternative exon in claudin-low cells is indicated by strong expression of the probeset for the
exclusion event (JUC0700130578_st) and relatively lower expression of probesets targeting
alternative exon inclusion event. Relative expression of the Fox2 splicing factor measured
by HJAY profiling (mean normalized) is shown at the bottom of the figure.
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Figure 3. PCR validation of breast cancer subtype-specific alternative splicing
Splicing differences predicted by exon junction microarrays for 5 genes shown in the figure
were examined by RT-PCR analysis in an extensive panel of breast cancer cell lines. RNA
from each cell line was amplified using primers in the flanking constitutive exons and the
products were analyzed using gel electrophoresis. The upper PCR band in each analysis
corresponds to an exon inclusion isoform while the lower band represents an exon exclusion
isoform. Results for these genes show that most claudin-low cell lines were spliced
differently than the other subtypes. Arrow indicates the position of the claudin-low-enriched
PCR product.
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Figure 4. Frequent association of Fox sites with breast cancer subtype-specific alternative exons
Diagrams represent the genomic regions spanning 1kb upstream to 1kb downstream of the
regulated exons. Locations of evolutionarily conserved occurrences of the Fox splicing
regulatory motif UGCAUG are indicated by filled ovals. Non-conserved sites present only
in the human genome are indicated by empty ovals. The highest frequency of Fox binding
sites occurs within 400nt (shaded) proximal to the intronic region however a few distal sites
are also evolutionarily conserved. For example, ENAH encodes two sites ~1.9 kb
downstream, ST7 encodes three sites ~1.8 kb downstream (one of which is conserved in
birds) and VPS39 encodes 1 site 1.5 kb upstream.
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Figure 5. Knockdown of Fox2 alters splicing in breast cancer cells
Panel A. Level of Fox2 siRNA knockdown achieved in four breast derived cell lines from
non-malignant tissue and three different malignant breast cancer subtypes. Irrelevant siRNA
and mock transfection serve as controls. Panel B. RT-PCR analysis of changes in splicing
efficiency induced by Fox2 knockdown in four luminal cell lines (LY2, 361, T47D, and
ZR75B; samples 1–4, respectively), four basal cell lines (BT20, HCC1569, HCC1954, and
HCC3153; samples 5–8) and four claudin low cell lines (BT549, HCC38, HS578T, and 157;
samples 9–12). Splicing in each cell line was compared after treatment with a control siRNA
(first lane of each pair), vs treatment with the Fox2 siRNA (second lane of each pair).
Identity of genes containing the 14 subtype-specific exons is given at the left. Upper PCR
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bands represent exon inclusion, while lower bands represent exon skipping products. For
VPS39, only the inclusion product was detected. For MARK3, the amplified region spans
two alternative exons of 27nt and 45nt and can generate four products. The 27nt exon is
subtype-specific (skipped in luminal but partially included in basal and claudin low) and
Fox2-dependent (abundance of the +27+45nt and +27−45nt bands is greatly reduced in
claudin low cells after Fox2 knockdown).
Lapuk et al. Page 21
Mol Cancer Res. Author manuscript; available in PMC 2011 July 6.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6. Comparative Pathway enrichment for AS and DE genes
One hundred forty (out of 156) AS genes and 222 (out of 224) DE genes were analyzed in
Ingenuity IPA 6.0 for pathway enrichment. Pathways enriched with AS genes are shown in
grey and with DE genes in black. A p-value cut off of 0.05 is shown with a vertical dotted
line.
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Table 2
Component gene lists from enriched pathways from Figure 6.
Pathway genes from 140 AS gene list
Pathway Name Component genes from Pathway
Axonal Guidance Signaling PTK2, SLIT3, PRKACB, GNAS, ADAM15, ITGA2, ITGA5, LIMK2, RASSF5, SEMA4A
Integrin Signaling PTK2, DDEF1, ITGA2, ITGA6, ITGA5, ACTN1
Actin Cytoskeleton Signaling PTK2, TIAM1, ITGA2, ITGA5, LIMK2, ACTN1
Tight Junction Signaling PRKACB, EPB41, TIAM1, TJP3, TJP1
PTEN Signaling PTK2, ITGA2, ITGA5
Androgen and Estrogen Metabolism STS
NF-kB Signaling PRKACB
Ephrin Receptor Signaling PTK2, GNAS, GRIN2D, ITGA2, ITGA5, LIMK2
ERK/MAPK Signaling PTK2, PRKACB, ITGA2, ITGA5
Xenobiotic Metabolism Signaling GSTM1, GSTP1, ALDH3A2, SULT1A1
Metabolism of Xenobiotics by Cytochrome P450 GSTM1, GSTP1
Pathway genes from 222 DE gene list
Pathway Name Component genes from Pathway
Axonal Guidance Signaling SEMA3A, SEMA3D, PIK3C2G, AKT3, EPHA3, BMP5, ITGA4
Ephrin Receptor Signaling PIK3C2G, AKT3, EPHA3, ITGA4
Integrin Signaling PIK3C2G, AKT3, ITGB6, ITGA4
Actin Cytoskeleton Signaling FGF2, PIK3C2G, ITGA4, MSN
PTEN Signaling GHR, AKT3, ITGA4
ERK/MAPK Signaling PLA2G4A, PIK3C2G, ELF5, ITGA4
Xenobiotic Metabolism Signaling IL1A, CAMK4, ALDH1A1, UGT2B4, PIK3C2G, IL1B, SULT1E1, SULT1B1, UGT2B28
Metabolism of Xenobiotics by Cytochrome P450 AKR1C1, UGT2B4, DHRS2, CYP4F11, UGT2B28
Androgen and Estrogen Metabolism AKR1C1, UGT2B4, SULT1E1, HSD17B2, UGT2B28
NF-kB Signaling IL18, IL1A, GHR, PIK3C2G, IL1B, AKT3
Wnt/β-catenin Signaling CDH2, MMP7, GJA1, SFRP2, AKT3, SFRP1, DKK1
p53 Signaling CCND2, PIK3C2G, AKT3, SERPINB5
FXR/RXR Activation IL18, IL1A, UGT2B4, IL1B, AKT3
Tyrosine Metabolism TYRP1, DHRS2 (includes EG:10202), TYR, DCT
Retinol Metabolism ALDH1A1, UGT2B4, UGT2B28
Pentose and Glucuronate Interconversions UCHL1, UGT2B4, UGT2B28
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